Lead Product(s) : Visugromab
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Visugromab in Cachexia International Trial
Details : Visugromab is a Antibody drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Cancer Cachexia.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 08, 2025
Lead Product(s) : Visugromab
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ponsegromab
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ponsegromab Safety and Effects In Advanced Pancreatic Cancer with Cachexia
Details : Ponsegromab is a Antibody drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Cachexia.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 25, 2025
Lead Product(s) : Ponsegromab
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Choline Chloride
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Choline Chloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Choline Deficiency.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 04, 2025
Lead Product(s) : Choline Chloride
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcifediol
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency
Details : Calcifediol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Vitamin D Deficiency.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 03, 2021
Lead Product(s) : Calcifediol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Setmelanotide Acetate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Long Term Extension Trial of Setmelanotide
Details : Setmelanotide is a Protein drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Obesity-associated with Leptin-melanocortin Pathway Defects.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 29, 2018
Lead Product(s) : Setmelanotide Acetate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nutritional Supplement
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral Nutritional Supplementation in Picky Eating Children
Details : Nutritional Supplement is a Dietary Supplement drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Malnutrition.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
August 14, 2015
Lead Product(s) : Nutritional Supplement
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vitamin B12
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II/ Phase III
Sponsor : Tribhuvan University, Nepal | NORCE Norwegian Research Centre AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Vitamin B12, Neurodevelopment and Growth in Nepal
Details : Vitamin B12 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Avitaminosis.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
October 23, 2014
Lead Product(s) : Vitamin B12
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II/ Phase III
Sponsor : Tribhuvan University, Nepal | NORCE Norwegian Research Centre AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obex
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Obex in Overweight and Obese Patients
Details : Obex is a Dietary Supplement drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Overweight.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
May 23, 2014
Lead Product(s) : Obex
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obex
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Obex, a Nutritional Supplement, in Overweight and Obese Spanish Women
Details : Obex is a Dietary Supplement drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
September 04, 2013
Lead Product(s) : Obex
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rutf-1
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II/ Phase III
Sponsor : UNICEF | Nutriset
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rutf-1 is a Dietary Supplement drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Malnutrition.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
June 28, 2013
Lead Product(s) : Rutf-1
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II/ Phase III
Sponsor : UNICEF | Nutriset
Deal Size : Inapplicable
Deal Type : Inapplicable